top of page

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Heading 4

Proteoz 2.5mg Injection

Proteoz 2.5mg Injection

Manufacturer/Marketed By : ZYDUS CADILA

$45.24 $28.95

Sidmex Inovia offers bulk export supply of Proteoz 2.5mg Injection (BORTEZOMIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.Documents, cold-chain shipping and tenders:...

BORTEZOMIB

Active Pharmaceutical Ingredient

Proteoz 2.5mg Injection

SKU PROTEOZ-2-5MG-INJECTION
Original price

$45.24

Sale price

$28.95

Sidmex Inovia offers bulk export supply of Proteoz 2.5mg Injection (BORTEZOMIB) for hospitals, distributors and tender buyers. Request a quote with your quantity and destination country.

Documents, cold-chain shipping and tenders: see our Export FAQ.

Priority markets: United Arab Emirates, Brazil, Turkey, Singapore, Kenya, Somalia, Ghana, Saudi Arabia, Mauritius, Nigeria, Tanzania, Senegal, Democratic Republic of the Congo, Mali. We also export worldwide, including:
Middle East: Oman, Qatar, Kuwait, Bahrain, Iraq, Jordan, Lebanon, Yemen, Iran
Africa: Egypt, Algeria, Morocco, Libya, Burkina Faso, Côte d'Ivoire, Gambia, Rwanda, Ethiopia, Djibouti, South Africa, Zimbabwe
Asia: Sri Lanka, Bangladesh, Nepal, Maldives, Philippines, Vietnam, Laos, Malaysia, Thailand, Taiwan
CIS & Eastern Europe: Russia, Kazakhstan, Uzbekistan, Azerbaijan, Georgia, Serbia, Latvia, Tajikistan
Latin America & Caribbean: Mexico, Chile, Peru, Colombia, Bolivia, Venezuela
Europe & Other: Switzerland, United Kingdom, Canada

Related products we supply: Alburel 20 gm/100 ml Injection

Proteoz 2.5mg Injection contains Bortezomib, a targeted anti-cancer medicine that belongs to a group of drugs known as proteasome inhibitors. It is primarily used to treat multiple myeloma, a type of blood cancer affecting plasma cells in the bone marrow, and mantle cell lymphoma, a rare form of cancer that impacts the lymph nodes. This medicine is often used in combination with other chemotherapy agents like cyclophosphamide, doxorubicin, dexamethasone, rituximab, thalidomide, or pegylated liposomal doxorubicin, especially in patients who have not received prior treatment and are not eligible for a blood stem cell transplant. Your doctor will decide the most suitable treatment plan based on your health status, disease stage, and other ongoing medications.

Active Pharmaceutical Ingredient

BORTEZOMIB

Uses

• Treatment of Multiple Myeloma
• Treatment of Mantle Cell Lymphoma

Benefits

Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.Add paragraph text. Click “Edit Text” to update the font, size and more. To change and reuse text themes, go to Site Styles.

Side Effects

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Most Common Side Effects

• Pneumonia
• Loss of appetite
• Sensitivity, tingling and burning sensation of the skin
• Nausea, vomiting, and diarrhoea
• Mouth ulcers
• Constipation
• Muscle and bone pain
• Hair loss
• Fever
• Reduction in blood cell count
• Reduced kidney function
• Shivering
• Infections
• Itching and redness
• Dehydration
• Stomach problems
• Difficulty sleeping, anxiety, mood swings, depressed mood

Common Side Effects

• Muscle cramps
• Confusion, visual disturbances, seizures, and headache
• Breathlessness
• Swelling of feet
• Changes in heartbeat
• High blood pressure
• Fainting and tiredness
• Cough and chest tightness

How To Use

This medicine is given by a trained healthcare provider either intravenously (into a vein) or subcutaneously (under the skin). It should not be self-administered.

Safety Advice

• Breast Feeding: Proteoz  2.5mg Injection is unsafe to use during breastfeeding. Please discuss with your physician when it is safe to restart breastfeeding after this treatment.
• Alcohol: It is unsafe to consume alcohol with this medication. Proteoz 2.5mg Injection may cause excessive drowsiness with alcohol. Please consult your doctor for more advice.
• Liver: Inform your physician before starting this treatment if you have Hepatitis infection or liver disease. Your physician will monitor your liver functions regularly.
• Lungs: It is unknown whether Proteoz 2.5mg Injection can be given to lung failure patients. Please consult your physician if you have any lung diseases.
• Driving: Avoid driving or using machinery if you experience side effects like fainting, dizziness, tiredness, or blurred vision.
• Pregnancy: Proteoz 2.5mg Injection is unsafe to use during pregnancy unless clearly necessary. Both women of childbearing potential and men must use an effective contraception method during and three months after treatment.

Disclaimer

Sidmex Inovia strives to provide accurate and reliable information; however, all content on this website, including product descriptions and compositions, is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.

Users are advised to consult a qualified healthcare professional before making any medical decisions. The information provided should not be used for self-diagnosis or self-medication.

All products listed are intended strictly for B2B and bulk inquiry purposes only. Sidmex Inovia does not promote direct consumer use and aims to support, not replace, the healthcare professional–patient relationship.

Product names, trademarks, and brands belong to their respective owners, and their use does not imply any affiliation or endorsement. Sidmex Inovia shall not be held responsible for any consequences arising from the use of the information provided on this website.

bottom of page